Study:
A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Rationale:
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab and fosbretabulin
tromethamine may stop the growth of ovarian cancer by blocking blood flow to the tumor. It
is not yet known whether bevacizumab is more effective when given together with
fosbretabulin tromethamine in treating ovarian, fallopian tube, and peritoneal cavity
cancer.
Purpose:
This randomized phase II trial is studying how well giving bevacizumab with or
without fosbretabulin tromethamine works in treating patients with ovarian epithelial,
fallopian tube, or peritoneal cavity cancer.
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic Cancer Center at Fai 216-476-9362
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer |
Biological: bevacizumab
Drug: fosbretabulin tromethamine |
Phase 2 |
Verified by
Gynecologic Oncology Group
September, 2012
Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT01305213
Study Type: Interventional
Study Design: Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Bradley J. Monk, MD., Principal Investigator